Register Login

IMUNON, INC. (IMNN)

(90% Positive) IMUNON, INC. (IMNN) Announces Enrollment Update for community Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot May 12, 2026, 12:06 p.m.

    📋 IMUNON, INC. (IMNN) - Clinical Trial Update

    Filing Date: 2026-05-12

    Accepted: 2026-05-12 08:05:36

    Event Type: Clinical Trial Update

    Event Details:

    IMUNON, INC. (IMNN) Announces Clinical Trial Update IMUNON, INC. (IMNN) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: community, results
    • Clinical Stage: Phase 2, Phase 3
    • Collaboration: IMUNON
    • Updated Timeline: Q1 2029
      • 001 in Women with Newly Diagnosed Advanced Ovarian Cancer – On March 25, 2026, the Company announced final data from the completed Phase 2 OVATION 2 clinical trial evaluating IMNN
      • 001 in combination with standard of care (SoC) neoadjuvant and adjuvant chemotherapy (N/ACT) in 112 women with newly diagnosed advanced ovarian cancer. IMUNON previously reported a median
      • month increase in overall survival (

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: IMUNON, INC.
    • Ticker Symbol: IMNN

Search

News categories